Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1

Nat Commun. 2024 Apr 5;15(1):2953. doi: 10.1038/s41467-024-47327-z.

Abstract

Heart failure with preserved ejection fraction (HFpEF) is associated with endothelial dysfunction. We have previously reported that statins prevent endothelial dysfunction through inhibition of microRNA-133a (miR-133a). This study is to investigate the effects and the underlying mechanisms of statins on HFpEF. Here, we show that statins upregulate the expression of a circular RNA (circRNA-RBCK1) which is co-transcripted with the ring-B-box-coiled-coil protein interacting with protein kinase C-1 (RBCK1) gene. Simultaneously, statins increase activator protein 2 alpha (AP-2α) transcriptional activity and the interaction between circRNA-RBCK1 and miR-133a. Furthermore, AP-2α directly interacts with RBCK1 gene promoter in endothelial cells. In vivo, lovastatin improves diastolic function in male mice under HFpEF, which is abolished by loss function of endothelial AP-2α or circRNA-RBCK1. This study suggests that statins upregulate the AP-2α/circRNA-RBCK1 signaling to suppress miR-133a in cardiac endothelial cells and prevent diastolic dysfunction in HFpEF.

MeSH terms

  • Animals
  • Endothelial Cells / metabolism
  • Heart Failure* / drug therapy
  • Heart Failure* / genetics
  • Heart Failure* / metabolism
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / pharmacology
  • Male
  • Mice
  • MicroRNAs* / metabolism
  • RNA, Circular / genetics
  • Stroke Volume / physiology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • MicroRNAs
  • RNA, Circular
  • Rbck1 protein, mouse